Shanghai Pharmaceuticals Holding Co., Ltd

SHSE:601607 Stock Report

Market Cap: CN¥61.8b

Shanghai Pharmaceuticals Holding Future Growth

Future criteria checks 1/6

Shanghai Pharmaceuticals Holding is forecast to grow earnings and revenue by 18.9% and 10.4% per annum respectively. EPS is expected to grow by 18.9% per annum. Return on equity is forecast to be 8.2% in 3 years.

Key information

18.9%

Earnings growth rate

18.9%

EPS growth rate

Healthcare earnings growth22.0%
Revenue growth rate10.4%
Future return on equity8.2%
Analyst coverage

Good

Last updated08 Jun 2024

Recent future growth updates

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Apr 01
Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Recent updates

Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

May 21
Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors

Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Apr 01
Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts

Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

Mar 16
Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down

We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

Feb 29
We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt

Earnings and Revenue Growth Forecasts

SHSE:601607 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026351,7946,7463,4426,1528
12/31/2025319,4055,8506505,76710
12/31/2024288,6325,2041,9257,59310
3/31/2024264,2213,793-7692,381N/A
12/31/2023260,2953,7682,2615,232N/A
9/30/2023254,8784,6004,1897,205N/A
6/30/2023252,8664,5313,7746,938N/A
3/31/2023241,3105,8841,8134,610N/A
12/31/2022231,9815,6172,0584,743N/A
9/30/2022229,4635,423-2,3131,978N/A
6/30/2022222,2945,221-1,6592,334N/A
3/31/2022221,1224,224-4433,671N/A
12/31/2021215,8245,0939435,061N/A
9/30/2021212,5595,3782,0134,571N/A
6/30/2021209,9825,6212,8635,310N/A
3/31/2021203,0615,5783,4856,337N/A
12/31/2020191,9094,4963,8356,845N/A
9/30/2020186,2714,2844,9828,288N/A
6/30/2020181,1564,2374,1187,705N/A
3/31/2020181,0073,9932,1945,277N/A
12/31/2019186,5664,0813,2696,022N/A
9/30/2019182,1003,9082,0304,334N/A
6/30/2019175,7814,1342,1674,077N/A
3/31/2019168,7053,9871,2963,193N/A
12/31/2018159,0843,8811,1923,135N/A
9/30/2018149,4174,2046552,536N/A
6/30/2018140,9473,6295202,470N/A
3/31/2018134,1043,5413172,368N/A
12/31/2017130,8473,521N/A2,649N/A
9/30/2017129,2793,428N/A2,483N/A
6/30/2017126,8483,389N/A2,401N/A
3/31/2017124,6193,306N/A1,995N/A
12/31/2016120,7653,196N/A1,947N/A
9/30/2016116,9933,155N/A1,989N/A
6/30/2016114,2623,075N/A1,672N/A
3/31/2016109,6673,033N/A1,819N/A
12/31/2015105,5172,877N/A1,349N/A
9/30/2015102,7232,857N/A1,265N/A
6/30/201599,3362,807N/A1,547N/A
3/31/201596,2502,738N/A1,758N/A
12/31/201492,3992,591N/A1,336N/A
9/30/201488,8812,477N/A1,161N/A
6/30/201483,5182,371N/A906N/A
3/31/201479,9072,174N/A667N/A
12/31/201378,2232,214N/A973N/A
9/30/201374,9882,155N/A997N/A
6/30/201373,1752,066N/A879N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 601607's forecast earnings growth (18.9% per year) is above the savings rate (2.9%).

Earnings vs Market: 601607's earnings (18.9% per year) are forecast to grow slower than the CN market (22.8% per year).

High Growth Earnings: 601607's earnings are forecast to grow, but not significantly.

Revenue vs Market: 601607's revenue (10.4% per year) is forecast to grow slower than the CN market (13.9% per year).

High Growth Revenue: 601607's revenue (10.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 601607's Return on Equity is forecast to be low in 3 years time (8.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.